Exact Mass: 707.2889736
Exact Mass Matches: 707.2889736
Found 143 metabolites which its exact mass value is equals to given mass value 707.2889736,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
HexNAc-(Hex)3
(a-D-mannosyl)2-b-D-mannosyl-N-acetylglucosamine
(alpha-D-mannosyl)2-beta-D-mannosyl-N-acetylglucosamine is an intermediate in aminosugars metabolism. It is substrate of Lysosomal alpha-mannosidase. [HMDB] (alpha-D-mannosyl)2-beta-D-mannosyl-N-acetylglucosamine is an intermediate in aminosugars metabolism. It is substrate of Lysosomal alpha-mannosidase. COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Lacto-N-tetraose
Lacto-N-tetraose (LNT) (CAS: 14116-68-8) is a neutral oligosaccharide present in human colostrum and milk. LNT is converted from lacto-N-triose II by the human enzyme beta-1,3-N-acetylglucosaminyltransferase 2 (beta3GnT2). Human milk is a unique reservoir of oligosaccharides. The presence of many of these oligosaccharides is determined genetically and is related to the Lewis blood group and secretor antigen status of each donor. Oligosaccharides in human milk represent a group of bioactive molecules that have evolved to be an abundant and diverse component of human milk, even though they have no direct nutritive value to the infant. A recent hypothesis proposes that they could be substrates for the development of the intestinal microflora and the mucosal immune system (PMID: 15629115, 11787695, 14530096, 17002410, 16277601, 11787692). Present in the free state in human milk
Neolactotetraose
Neolactotetraose (CAS: 13007-32-4), also known as lacto-N-neotetraose (LNnt), is a common oligosaccharide present in human breast milk. After lactose and lipids, human milk oligosaccharides (HMOs) are quantitatively the third largest and most diverse component of breast milk. These small mass HMOs are selectively metabolized by select bifidobacterial strains and represent a potential new class of bioactive molecules functioning as prebiotics to facilitate protective gut colonization in breast-fed newborns. The oligosaccharide composition of human milk varies among individuals. The geographical origin of the donors is one of the factors that account for this variability. This can be explained by genetically determined traits that are not uniformly distributed (PMID: 10420591, 10697138, 1370278, 14533820, 16239538, 16441441, 17101655, 17372007, 1910009, 2452383, 2474254, 2988366, 3926023, 6083447, 6798116, 6874813, 8193150, 8416736, 9353017).
Alpha-D-Manp-(1 -> 2)-a-D-Manp-(1 -> 2)-a-D-Manp-(1 -> 3)-b-D-Manp-(1 -> 4)-D-GlcNAcp
alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-beta-D-Manp-(1->4)-D-GlcNAcp is a pentasaccharide found in the urine of patients with mannosidosis (PMID: 953057). It is a glycan structure of human milk glycoprotein glycopeptides (PMID: 6698017). This oligosaccharide is derived from high-mannose and different complex and hybrid asparagine-linked glycans and from the storage products in alpha-mannosidosis. The human liver lysosomal alpha-mannosidase (EC 3.2.1.24) enzyme that specifically hydrolyzes all alpha(1-2)-, alpha(1-3)- and alpha(1-6)-mannosidic linkages in these glycans. (PMID: 1872811) [HMDB] Alpha-D-Manp-(1 -> 2)-a-D-Manp-(1 -> 2)-a-D-Manp-(1 -> 3)-b-D-Manp-(1 -> 4)-D-GlcNAcp is a pentasaccharide found in the urine of patients with mannosidosis (PMID: 953057). It is a glycan structure of human milk glycoprotein glycopeptides (PMID: 6698017). This oligosaccharide is derived from high-mannose and different complex and hybrid asparagine-linked glycans and from the storage products in alpha-mannosidosis. The human liver lysosomal alpha-mannosidase (EC 3.2.1.24) enzyme that specifically hydrolyzes all alpha(1-2)-, alpha(1-3)- and alpha(1-6)-mannosidic linkages in these glycans. (PMID: 1872811).
Gangliotetraose
beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc
2-[[(2R)-2-[Bis(carboxymethyl)amino]-2-[(4,4-diphenylcyclohexyl)-hydroxyphosphoryl]oxyethyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid
beta-Galp-(1->3)-beta-GlcpNAc-(1->3)-beta-Galp-(1->4)-Glc|Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc|lacto-N-tetraose|O4-[O3-(2-acetylamino-O3-beta-D-galactopyranosyl-2-deoxy-beta-D-glucopyranosyl)-beta-D-galactopyranosyl]-D-glucose|O4-[O3-(2-Acetylamino-O3-beta-D-galactopyranosyl-2-desoxy-beta-D-glucopyranosyl)-beta-D-galactopyranosyl]-D-glucose
Met Trp Trp Trp
Trp Met Trp Trp
Trp Trp Met Trp
Trp Trp Trp Met
Neolactotetraose
Alpha-D-Manp-(1 -> 2)-a-D-Manp-(1 -> 2)-a-D-Manp-(1 -> 3)-b-D-Manp-(1 -> 4)-D-GlcNAcp
Dihydroergocristine mesylate
C36H45N5O8S (707.2988690000001)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc
Isolated from human milk
beta-D-Gal-(1->4)-beta-D-glcnac-(1->3)-beta-D-gal-(1->4)-D-GLC
2-[[(2R)-2-[Bis(carboxymethyl)amino]-2-[(4,4-diphenylcyclohexyl)-hydroxyphosphoryl]oxyethyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid
alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc
beta-D-Galp-(1->4)-[beta-D-Galp-(1->4)-beta-D-Glcp-(1->6)]-beta-D-GlcpNAc
N-[(2S,3R,4R,5R,6R)-2-[(2R,3R,4S,5S,6R)-2-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
beta-D-Glcp-(1->6)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp
beta-D-Galp-(1->4)-beta-D-Glcp-(1->6)-beta-D-GlcpNAc-(1->3)-beta-D-Galp
beta-D-Galp-(1->4)-[beta-D-Glcp-(1->6)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp
beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->3)-D-Glc
alpha-D-Galp-(1->3)-[alpha-D-Galp-(1->4)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc
beta-D-Manp-(1->3)-beta-D-Manp-(1->3)-alpha-L-Rhap-(1->3)-beta-D-GlcpO[CH2]3NH2
alpha-D-Galp-(1->3)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp
6-[2-[(E,3E)-3-(9-ethyl-6,8,8-trimethyl-2-phenylpyrano[3,2-g]quinolin-4-ylidene)prop-1-enyl]-3,3-dimethyl-5-sulfoindol-1-ium-1-yl]hexanoic acid
C42H47N2O6S+ (707.3154662000002)
(a-D-mannosyl)2-b-D-mannosyl-N-acetylglucosamine
COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
N-[(2R,3R,4S,5R)-4-{[(2S,3S,4S,5R,6R)-4-{[(2R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3,5,6-trihydroxy-1-oxohexan-2-yl]acetamide
8-benzyl-10,17,24-trihydroxy-15-isopropyl-26-methyl-22-(sec-butyl)-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one
(2s,8r,15r,18r,22s,25s,26r)-8-benzyl-10,17,24-trihydroxy-15-isopropyl-26-methyl-22-(sec-butyl)-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one
n-(1-oxo-1-{[(8e,10e,16z)-3,15,24,28-tetrahydroxy-5-methoxy-14,16-dimethyl-22-thia-2,25-diazatricyclo[18.7.1.0²¹,²⁶]octacosa-1(27),2,6,8,10,16,20(28),21(26),24-nonaen-13-yl]oxy}propan-2-yl)cyclohex-1-ene-1-carboximidic acid
C38H49N3O8S (707.3240194000001)
2,7-bis(acetyloxy)-8-(benzoyloxy)-6-hydroxy-5,5,9,13-tetramethyl-12-[(methylamino)methyl]-14-oxo-15,16-dioxatetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-11-yl benzoate
n-(1-oxo-1-{[(6e,8e,10e,16z)-3,15,24,28-tetrahydroxy-5-methoxy-14,16-dimethyl-22-thia-2,25-diazatricyclo[18.7.1.0²¹,²⁶]octacosa-1(27),2,6,8,10,16,20(28),21(26),24-nonaen-13-yl]oxy}propan-2-yl)cyclohex-1-ene-1-carboximidic acid
C38H49N3O8S (707.3240194000001)
n-(1-oxo-1-{[(4z,10e,12e)-6,18,24,28-tetrahydroxy-16-methoxy-5,7-dimethyl-22-thia-19,25-diazatricyclo[18.7.1.0²¹,²⁶]octacosa-1(27),4,10,12,14,18,20(28),21(26),24-nonaen-8-yl]oxy}propan-2-yl)cyclohex-1-ene-1-carboximidic acid
C38H49N3O8S (707.3240194000001)
(1s,2r,4s,6s,7s,8r,9s,10s,11r,12s,13r)-2,7-bis(acetyloxy)-8-(benzoyloxy)-6-hydroxy-5,5,9,13-tetramethyl-12-[(methylamino)methyl]-14-oxo-15,16-dioxatetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-11-yl benzoate
4,7-dihydroxy-6-[(3-hydroxy-4,6-dimethyloctanoyl)oxy]-1-{4-[(1-hydroxyethylidene)amino]-5-methyl-3-methylidene-6-phenylhexyl}-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
(2s,8r,15r,18r,22s,25s,26r)-8-benzyl-22-[(2s)-butan-2-yl]-10,17,24-trihydroxy-15-isopropyl-26-methyl-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one
n-(1-oxo-1-{[(4e,10z,12e,14e)-6,18,24,28-tetrahydroxy-16-methoxy-5,7-dimethyl-22-thia-19,25-diazatricyclo[18.7.1.0²¹,²⁶]octacosa-1(27),4,10,12,14,18,20(28),21(26),24-nonaen-8-yl]oxy}propan-2-yl)cyclohex-1-ene-1-carboximidic acid
C38H49N3O8S (707.3240194000001)